With the recent intensification of the conflict between Russia and Ukraine, the United States and Russia are fighting in secret and speculating behind the scenes, and the energy field is becoming more and more restless, and domestic oil prices will inevitably have a chain reaction.
2. The Russian ruble oscillated, and the fluctuation of RMB exchange rate against the ruble expanded to 10%.
Since the escalation of the conflict between Russia and Ukraine, Russia's economy and finance have been sanctioned. The biggest drop of the ruble against the US dollar is nearly 100%, and the biggest drop against the RMB is also over 80%. Due to the obvious fluctuation of ruble exchange rate, China Foreign Exchange Trading Center announced that it would expand the fluctuation range of spot trading price of RMB against ruble to 10%.
3. Jingdong Logistics will acquire 66.49% of Debon shares.
Jingdong Logistics and Debon Logistics have reached a strategic cooperation, and Jingdong Logistics will acquire 66.49% of Debon shares. The two sides will carry out in-depth cooperation in the fields of express delivery, cross-border, warehousing and supply chain, and will continue to maintain the independent operation of the brand and team.
4. Pfizer Paciclovir tablets will be approved for imitation next week, and will be available before 65438+February at the earliest.
The Pharmaceutical Patent Pool Organization plans to announce the list of pharmaceutical companies approved to copy Pfizer's oral drug Paxillovid in COVID-19 next week, and pharmaceutical companies may prepare to provide the first batch of Paxillovid tablets before 65438+February this year. Due to production and regulatory obstacles and the complexity of the raw materials of the drug, a larger number of drugs may not enter the market until May 2023. Five China pharmaceutical companies were shortlisted.